Fresh from a European cancer conference that was all about antibody-drug conjugates (ADCs), GSK has turned to French biotech ...

Prostate cancer screening for men over 70 is complex, with current recommendations against routine PSA testing due to slow ...

NICE recommendation of darolutamide plus hormone therapy for metastatic prostate cancer offers around 6000 patients in ...

The National Institute for Health and Care Excellence (NICE) has recommended darolutamide in combination with androgen ...

NICE recommends Bayer’s Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option for patients with hormone-sensitive metastatic prostate cancer Nubeqa® (darolutamide) plus ...

A globally-renowned prostate cancer surgeon shares the latest advancements in the field and stresses the importance of early ...

Patients with metastatic hormone-sensitive prostate cancer (mHSPC) lived significantly longer without disease progression ...

The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.

GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...

Sept. 18, 2025 -- About 1 in 8 men will face a prostate cancer diagnosis. Early-stage prostate cancer often has no symptoms—so how should men approach screening and advocacy? What disparities do Black ...

Zoledronic acid reduced fracture risk by 27% in men with metastatic prostate cancer receiving ADT in the STAMPEDE trial. Patients with non-metastatic disease showed no significant fracture benefit ...

BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen ...